Corrigendum to "FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion" [Int. J. Cardiol. 202 (2016) 52-58].
Berger RMF, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Gali? N, Ivy DD, Ja?s X, Miera O, Rosenzweig EB, Efficace M, Kusic-Pajic A, Beghetti M. Corrigendum to "FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion" [Int. J. Cardiol. 202 (2016) 52-58]. Int J Cardiol. 2016 11 15; 223:1072-1073.